RECRUITING

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

Talk to us

Conditions

CancerCancer GenomicsTumor Sequencing

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

Official Title

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

Quick Facts

Study Start:2013-11-04
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02090530

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. A histologically or cytologically confirmed diagnosis of cancer
  2. 2. Patients with any malignancy.
  3. 3. Patients must have tumor suitable for research tumor biopsy (as assessed by trained specialists in interventional radiology) and Patients are medically fit to undergo a tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a tumor suitable for biopsy but have another tissue available for molecular evaluation.
  4. 4. Procedure-specific signed informed consent prior to initiation of any study-related procedures.
  5. 5. Women and minorities are included in this protocol.
  6. 6. Patients with multiple malignancies remain eligible.
  7. 7. Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible.
  1. 1. It is the enrolling study physicians discretion to decide if a patient is not fit enough to undergo tissue biopsy.
  2. 2. Patients who are incarcerated are not eligible to participate.

Contacts and Locations

Study Contact

Ohio State University Comprehensive Cancer Center
CONTACT
1-800-293-5066
OSUCCCClinicaltrials@osumc.edu
Sameek Roychowdhury, MD, PhD
CONTACT
614-685-5842
Sameek.Roychowdhury@osumc.edu

Principal Investigator

Sameek Roychowdhury, MD, PhD
PRINCIPAL_INVESTIGATOR
Ohio State University Wexner Medical Center

Study Locations (Sites)

Ohio State University Wexner Medical Center
Columbus, Ohio, 43210
United States

Collaborators and Investigators

Sponsor: Ohio State University Comprehensive Cancer Center

  • Sameek Roychowdhury, MD, PhD, PRINCIPAL_INVESTIGATOR, Ohio State University Wexner Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2013-11-04
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2013-11-04
Study Completion Date2024-12-31

Terms related to this study

Keywords Provided by Researchers

  • Cancer Genomics
  • Tumor Sequencing

Additional Relevant MeSH Terms

  • Cancer